Doppler echocardiographic assessment of the effects of inhaled long-acting β2-agonists on pulmonary artery pressure in COPD patients

Mario Cazzola, Antonio Mantero, Pierachille Santus, Paolo Carlucci, Michele Mondoni, Laura Bosotti, Stefano Centanni

Research output: Contribution to journalArticle

Abstract

Increase in pulmonary artery pressure (PAP), which is common in severe chronic obstructive pulmonary disease (COPD), is a predictor of mortality independent of airflow limitation. β-agonists might slightly attenuate this increase because they exert a vasodilating effect on pulmonary circulation when systematically administered. We have investigated the acute effects of salmeterol and formoterol on echocardiographic systolic pulmonary artery pressure (sPAP) in 20 patients with COPD and a sPAP greater than 20 mmHg at rest. Acute haemodynamic responses to inhaled formoterol or salmeterol were assessed in all patients, in a randomized, double-blind double-dummy fashion. On two consecutive days, patients received, in a randomized order, formoterol 12 μg via Turbuhaler plus placebo via Diskus or salmeterol 50 μg via Diskus plus placebo via Turbuhaler. Transthoracic Doppler echocardiography measurements of sPAP were made before and 15, 30, 60 and 180 min after bronchodilator inhalation. Lung function, pulse oximetry and heart rate were also monitored at the same times. Mean sPAP significantly (p <0.05) decreased in comparison with baseline at 15, 30, and 60 min post inhalation but returned towards control levels at 180 min after both salmeterol and formoterol. There was no correlation between the maximum increase in FEV1 and maximum decrease in sPAP either after inhalation of salmeterol (r2 = 0.071) or after that of formoterol (r2 = 0.0006). The increases in FEV1 in comparison with baseline were always significant (p <0.05) from 15 to 180 min post inhalation after either salmeterol or formoterol. Neither pulse oximetry nor heart rate changed in a significant manner (p > 0.05). This study demonstrated that salmeterol and formoterol were equally beneficial for pulmonary haemodynamics in patients with COPD. A direct vasodilatation due to the activation of β-adrenoceptors that are present in pulmonary vessels is a likely mechanism of their action in inducing the decrease in sPAP.

Original languageEnglish
Pages (from-to)258-264
Number of pages7
JournalPulmonary Pharmacology and Therapeutics
Volume20
Issue number3
DOIs
Publication statusPublished - Jun 2007

    Fingerprint

Keywords

  • COPD
  • Formoterol
  • Pulmonary artery pressure
  • Salmeterol
  • Transthoracic Doppler echocardiography

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology

Cite this